CD72 negatively regulates KIT-mediated responses in human mast cells

Journal of Immunology

Volumn 184, Issue 5, 2010, Pages 2468-2475

  Kataoka, Tatsuki R ^a,b   Kumanogoh, Atsushi ^c,d   Bandara, Geethani ^a   Metcalfe, Dean D ^a   Gilfillan, Alasdair M ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b HYOGO COLLEGE OF MEDICINE   (Japan)

^c OSAKA UNIVERSITY   (Japan)

^d OSAKA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; BU40 ANTIBODY; CD72 ANTIGEN; CHEMOKINE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PROTEIN TYROSINE PHOSPHATASE SHP 2; STEM CELL FACTOR; UNCLASSIFIED DRUG; B LYMPHOCYTE ANTIGEN; CCL2 PROTEIN, HUMAN; CD100 ANTIGEN; CD72 PROTEIN, HUMAN; IMMUNOGLOBULIN E RECEPTOR; LEUKOCYTE ANTIGEN; MONOCLONAL ANTIBODY; MONOCYTE CHEMOTACTIC PROTEIN 1; PROTEIN TYROSINE PHOSPHATASE SHP 1; RECOMBINANT PROTEIN; SEMAPHORIN; STEM CELL FACTOR RECEPTOR;

ARTICLE; B LYMPHOCYTE; CELL PROLIFERATION; CHEMOTAXIS; CONTROLLED STUDY; DOWN REGULATION; HUMAN; HUMAN CELL; LIGATION; MAST CELL; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; CELL CULTURE; CELL CYCLE; CELL STRAIN U937; CYTOLOGY; DEGRANULATION; DRUG EFFECT; FLOW CYTOMETRY; GENETICS; IMMUNOLOGY; METABOLISM; PHOSPHORYLATION; PHYSIOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL LINE; WESTERN BLOTTING;

ANTIBODIES, MONOCLONAL; ANTIGENS, CD; ANTIGENS, DIFFERENTIATION, B-LYMPHOCYTE; BLOTTING, WESTERN; CELL CYCLE; CELL DEGRANULATION; CELL LINE, TUMOR; CELL PROLIFERATION; CELLS, CULTURED; CHEMOKINE CCL2; CHEMOTAXIS; FLOW CYTOMETRY; HUMANS; MAST CELLS; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; PHOSPHORYLATION; PROTEIN TYROSINE PHOSPHATASE, NON-RECEPTOR TYPE 6; PROTO-ONCOGENE PROTEINS C-KIT; RECEPTORS, IGE; RECOMBINANT PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SEMAPHORINS; STEM CELL FACTOR; U937 CELLS;

EID: 77951907700     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.0902450     Document Type: Article

References (50)

1. Kraft, S., and J. P. Kinet. 2007. New developments in FcεRI regulation, function and inhibition. Nat. Rev. Immunol. 7: 365-378.
2. Okayama, Y., and T. Kawakami. 2006. Development, migration, and survival of mast cells. Immunol. Res. 34: 97-115.
3. Metcalfe, D. D. 2008. Mast cells and mastocytosis. Blood 112: 946-956.
4. Nagata, H., A. S. Worobec, C. K. Oh, B. A. Chowdhury, S. Tannenbaum, Y. Suzuki, and D. D. Metcalfe. 1995. Identification of a point mutation in the catalytic domain of the protooncogene c-kit in peripheral blood mononuclear cells of patients who have mastocytosis with an associated hematologic disorder. Proc. Natl. Acad. Sci. USA 92: 10560-10564.
5. Furitsu, T., T. Tsujimura, T. Tono, H. Ikeda, H. Kitayama, U. Koshimizu, H. Sugahara, J. H. Butterfield, L. K. Ashman, Y. Kanayama, et al. 1993. Identification of mutations in the coding sequence of the proto-oncogene c-kit in a human mast cell leukemia cell line causing ligand-independent activation of c-kit product. J. Clin. Invest. 92: 1736-1744.
6. Gilfillan, A. M., and C. Tkaczyk. 2006. Integrated signalling pathways for mast-cell activation. Nat. Rev. Immunol. 6: 218-230.
7. Jensen, B. M., C. Akin, and A. M. Gilfillan. 2008. Pharmacological targeting of the KIT growth factor receptor: a therapeutic consideration for mast cell disorders. Br. J. Pharmacol. 154: 1572-1582.
8. Gilfillan, A. M., R. D. Peavy, and D. D. Metcalfe. 2009. Amplification mechanisms for the enhancement of antigen-mediated mast cell activation. Immunol. Res. 43: 15-24.
9. Li, L., and Z. Yao. 2004. Mast cell and immune inhibitory receptors. Cell. Mol. Immunol. 1: 408-415.
10. Cherwinski, H. M., C. A. Murphy, B. L. Joyce, M. E. Bigler, Y. S. Song, S. M. Zurawski, M. M. Moshrefi, D. M. Gorman, K. L. Miller, S. Zhang, et al. 2005. The CD200 receptor is a novel and potent regulator of murine and human mast cell function. J. Immunol. 174: 1348-1356.
11. Bachelet, I., A. Munitz, B. Berent-Maoz, D. Mankuta, and F. Levi-Schaffer. 2008. Suppression of normal and malignant kit signaling by a bispecific antibody linking kit with CD300a. J. Immunol. 180: 6064-6069.
12. Unkeless, J. C., and J. Jin. 1997. Inhibitory receptors, ITIM sequences and phosphatases. Curr. Opin. Immunol. 9: 338-343.
13. Wu, H. J., and S. Bondada. 2009. CD72, a coreceptorwith both positive and negative effects on B lymphocyte development and function. J. Clin. Immunol. 29: 12-21.
14. Kumanogoh, A., C. Watanabe, I. Lee, X. Wang, W. Shi, H. Araki, H. Hirata, K. Iwahori, J. Uchida, T. Yasui, et al. 2000. Identification of CD72 as a lymphocyte receptor for the class IV semaphorin CD100: a novel mechanism for regulating B cell signaling. Immunity 13: 621-631.
15. Kirshenbaum, A. S., J. P. Goff, T. Semere, B. Foster, L. M. Scott, and D. D. Metcalfe. 1999. Demonstration that human mast cells arise from a progenitor cell population that is CD34(+), c-kit(+), and expresses aminopeptidase N (CD13). Blood 94: 2333-2342.
16. Kirshenbaum, A. S., C. Akin, Y. Wu, M. Rottem, J. P. Goff, M. A. Beaven, V. K. Rao, and D. D. Metcalfe. 2003. Characterization of novel stem cell factor responsive human mast cell lines LAD 1 and 2 established from a patient with mast cell sarcoma/leukemia; activation following aggregation of FcεRI or FcγRI. Leuk. Res. 27: 677-682.
17. Butterfield, J. H., D. Weiler, G. Dewald, and G. J. Gleich. 1988. Establishment of an immature mast cell line from a patient with mast cell leukemia. Leuk. Res. 12: 345-355.
18. Sundström, M., H. Vliagoftis, P. Karlberg, J. H. Butterfield, K. Nilsson, D. D. Metcalfe, and G. Nilsson. 2003. Functional and phenotypic studies of two variants of a human mast cell line with a distinct set of mutations in the c-kit proto-oncogene. Immunology 108: 89-97. (Pubitemid 36110869)
19. Ishida, I., A. Kumanogoh, K. Suzuki, S. Akahani, K. Noda, and H. Kikutani. 2003. Involvement of CD100, a lymphocyte semaphorin, in the activation of the human immune system via CD72: implications for the regulation of immune and inflammatory responses. Int. Immunol. 15: 1027-1034.
20. Kim, M. S., H. S. Kuehn, D. D. Metcalfe, and A. M. Gilfillan. 2008. Activation and function of the mTORC1 pathway in mast cells. J. Immunol. 180: 4586-4595.
21. Kataoka, T. R., and Y. Nishizawa. 2008. Stat4 suppresses the proliferation of connective tissue-type mast cells. Lab. Invest. 88: 856-864.
22. Baghestanian, M., R. Hofbauer, H. P. Kiener, H. C. Bankl, F. Wimazal, M. Willheim, O. Scheiner, W. Füreder, M. R. Müller, D. Bevec, et al. 1997. The c-kit ligand stem cell factor and anti-IgE promote expression of monocyte chemoattractant protein-1 in human lung mast cells. Blood 90: 4438-4449. (Pubitemid 27508449)
23. Schwarting, R., R. Castello, G. Moldenhauer, A. Pezzutto, I. von Hoegen, W. D. Ludwig, J. R. Parnes, and B. Dörken. 1992. Human Lyb-2 homolog CD72 is a marker for progenitor B-cell leukemias. Am. J. Hematol. 41: 151-158.
24. Adachi, T., H. Flaswinkel, H. Yakura, M. Reth, and T. Tsubata. 1998. The B cell surface protein CD72 recruits the tyrosine phosphatase SHP-1 upon tyrosine phosphorylation. J. Immunol. 160: 4662-4665. (Pubitemid 28215297)
25. Wu, Y., M. J. Nadler, L. A. Brennan, G. D. Gish, J. F. Timms, N. Fusaki, J. Jongstra-Bilen, N. Tada, T. Pawson, J. Wither, et al. 1998. The B-cell transmembrane protein CD72 binds to and is an in vivo substrate of the protein tyrosine phosphatase SHP-1. Curr. Biol. 8: 1009-1017.
26. Zhang, Z., K. Shen, W. Lu, and P. A. Cole. 2003. The role of C-terminal tyrosine phosphorylation in the regulation of SHP-1 explored via expressed protein ligation. J. Biol. Chem. 278: 4668-4674.
27. Nilsson, G., J. H. Butterfield, K. Nilsson, and A. Siegbahn. 1994. Stem cell factor is a chemotactic factor for human mast cells. J. Immunol. 153: 3717-3723. (Pubitemid 24313877)
28. Alcón, V. L., C. Luther, D. Balce, and F. Takei. 2009. B-cell co-receptor CD72 is expressed on NK cells and inhibits IFN-γ production but not cytotoxicity. Eur. J. Immunol. 39: 826-832.
29. Kepley, C. L., S. Taghavi, G. Mackay, D. Zhu, P. A. Morel, K. Zhang, J. J. Ryan, L. S. Satin, M. Zhang, P. P. Pandolfi, and A. Saxon. 2004. Co-aggregation of FcγRII with FcεRI on human mast cells inhibits antigen-induced secretion and involves SHIP-Grb2-Dok complexes. J. Biol. Chem. 279: 35139-35149.
30. Kumanogoh, A., and H. Kikutani. 2001. The CD100-CD72 interaction: a novel mechanism of immune regulation. Trends Immunol. 22: 670-676. (Pubitemid 34008603)
31. Ito, A., M. Hagiyama, and J. Oonuma. 2008. Nerve-mast cell and smooth muscle-mast cell interaction mediated by cell adhesion molecule-1, CADM1. J. Smooth Muscle Res. 44: 83-93.
32. Subbarao, B., and D. E. Mosier. 1983. Induction of B lymphocyte proliferation by monoclonal anti-Lyb 2 antibody. J. Immunol. 130: 2033-2037. (Pubitemid 13086727)
33. Subbarao, B., and D. E. Mosier. 1984. Activation of B lymphocytes by monovalent anti-Lyb-2 antibodies. J. Exp. Med. 159: 1796-1801.
34. Snow, E. C., J. J. Mond, and B. Subbarao. 1986. Enhancement by monoclonal anti-Lyb-2 antibody of antigen-specific B lymphocyte expansion stimulated by TNP-Ficoll and T lymphocyte-derived factors. J. Immunol. 137: 1793-1796.
35. Pan, C., N. Baumgarth, and J. R. Parnes. 1999. CD72-deficient mice reveal nonredundant roles of CD72 in B cell development and activation. Immunity 11: 495-506. (Pubitemid 29504204)
36. Li, D. H., J. W. Tung, I. H. Tarner, A. L. Snow, T. Yukinari, R. Ngernmaneepothong, O. M. Martinez, and J. R. Parnes. 2006. CD72 down-modulates BCR-induced signal transduction and diminishes survival in primary mature B lymphocytes. J. Immunol. 176: 5321-5328.
37. Wu, H. J., C. Venkataraman, S. Estus, C. Dong, R. J. Davis, R. A. Flavell, and S. Bondada. 2001. Positive signaling through CD72 induces mitogen-activated protein kinase activation and synergizes with B cell receptor signals to induce X-linked immunodeficiency B cell proliferation. J. Immunol. 167: 1263-1273.
38. Nomura, T., H. Han, M. C. Howard, H. Yagita, H. Yakura, T. Honjo, and T. Tsubata. 1996. Antigen receptor-mediated B cell death is blocked by signaling via CD72 or treatment with dextran sulfate and is defective in autoimmunity-prone mice. Int. Immunol. 8: 867-875.
39. Shi, W., A. Kumanogoh, C. Watanabe, J. Uchida, X. Wang, T. Yasui, K. Yukawa, M. Ikawa, M. Okabe, J. R. Parnes, et al. 2000. The class IV semaphorin CD100 plays nonredundant roles in the immune system: defective B and T cell activation in CD100-deficient mice. Immunity 13: 633-642.
40. Adachi, T., C. Wakabayashi, T. Nakayama, H. Yakura, and T. Tsubata. 2000. CD72 negatively regulates signaling through the antigen receptor of B cells. J. Immunol. 164: 1223-1229. (Pubitemid 30067233)
41. Baba, T., N. Fusaki, A. Aoyama, D. H. Li, R. M. Okamura, J. R. Parnes, and N. Hozumi. 2005. Dual regulation of BCR-mediated growth inhibition signaling by CD72. Eur. J. Immunol. 35: 1634-1642.
42. Paulson, R. F., S. Vesely, K. A. Siminovitch, and A. Bernstein. 1996. Signalling by the W/Kit tyrosine kinase is negatively regulated in vivo by the tyrosine phosphatase Shp1. Nat. Genet. 13: 309-315.
43. Rivera, J., and A. Olivera. 2007. Src family kinases and lipid mediators in control of allergic inflammation. Immunol. Rev. 217: 255-268.
44. Hibbs, M. L., and K. W. Harder. 2006. The duplicitous nature of the Lyn tyrosine kinase in growth factor signaling. Growth Factors 24: 137-149.
45. Kozlowski, M., L. Larose, F. Lee, D. M. Le, R. Rottapel, and K. A. Siminovitch. 1998. SHP-1 binds and negatively modulates the c-Kit receptor by interaction with tyrosine 569 in the c-Kit juxtamembrane domain. Mol. Cell. Biol. 18: 2089-2099.
46. Xie, Z. H., J. Zhang, and R. P. Siraganian. 2000. Positive regulation of c-Jun N-terminal kinase and TNF-α production but not histamine release by SHP-1 in RBL-2H3 mast cells. J. Immunol. 164: 1521-1528.
47. You, M., and Z. Zhao. 1997. Positive effects of SH2 domain-containing tyrosine phosphatase SHP-1 on epidermal growth factor- and interferon-γ- stimulated activation of STAT transcription factors in HeLa cells. J. Biol. Chem. 272: 23376-23381.
48. Ueda, S., M. Mizuki, H. Ikeda, T. Tsujimura, I. Matsumura, K. Nakano, H. Daino, Z. Honda Zi, J. Sonoyama, H. Shibayama, et al. 2002. Critical roles of c-Kit tyrosine residues 567 and 719 in stem cell factor-induced chemotaxis: contribution of src family kinase and PI3-kinase on calcium mobilization and cell migration. Blood 99: 3342-3349. (Pubitemid 34525315)
49. O'Laughlin-Bunner, B., N. Radosevic, M. L. Taylor, C. Shivakrupa, C. DeBerry, D. D. Metcalfe, M. Zhou, C. Lowell, and D. Linnekin. 2001. Lyn is required for normal stem cell factor-induced proliferation and chemotaxis of primary hematopoietic cells. Blood 98: 343-350.
50. Wong, C. K., C. M. Tsang, W. K. Ip, and C. W. Lam. 2006. Molecular mechanisms for the release of chemokines from human leukemic mast cell line (HMC)-1 cells activated by SCF and TNF-α: roles of ERK, p38 MAPK, and NF-kappaB. Allergy 61: 289-297.